DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Spark Therapeutics
Spark Therapeutics
CADTH ISSUES in EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies
Spark Therapeutics and Pfizer Announce That SPK-9001, An
First Gene Therapy Fda-Approved for An
Landscape Review and Evidence Map of Gene Therapy, Part 2
Luxturna: FDA Documents Reveal the Value of a Costly Gene Therapy
Luxturna™ (Voretigene Neparvovec-Rzyl)
Spark Therapeutics Presents Updated Preliminary Data from Hemophilia
Fda Advisory Committee Briefing Document
Medical Policy #911 Gene Therapy for Inherited Retinal Dystrophy
Spark Therapeutics Presents Updated Interim Hemophilia B Data
FDA Approves Spark Therapeutics' LUXTURNA
An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials
The Development Timeline of LUXTURNA® (Voretigene Neparvovec-Rzyl)
Top View